This ER+ BC trial uniquely targets the upregulation of the cyclin-dependent kinase 4/5 pathway and immune evasion, which have been shown to influence BCC dormancy exit, in addition to autophagy, for which a dormancy metabolic mechanism has been described (Clinicaltrials.gov identifier: NCT04841148) [83]. This evidence concerns the gene CDK4 and breast cancer.